Ezogabine Bhatt

Ezogabine Bhatt is a clinical investigator specializing in early-phase trials of bispecific antibodies in hematologic malignancies at Dana-Farber Cancer Institute. His work encompasses dose optimization, toxicity management, and biomarker correlates for CD3-engaging bispecifics including BCMA-targeted and CD20-targeted antibodies. He has contributed to clinical protocols for cytokine release syndrome (CRS) mitigation with bispecific antibody step-up dosing. His research bridges first-in-human trial design with the regulatory path for bispecific antibody approvals.